November 2008 - Page 67 of 76

MondayNov 03, 2008 4:30 am

Nuinsco Resources Limited (TSX: NWI CN)

Nuinsco Resources Limited (TSX: NWI CN), a growth-oriented, multi-commodity mineral exploration and development company, is focused on growing through the exploration and development of world-class mineralized belts in Canada and Turkey. The company also holds equity positions in near-production Victory Nickel Inc. (TSX:Ni), polymetallic producer Gold Hawk Resources Inc. (TSXV:CGK) and copper and gold producer Campbell Resources Inc. (TSX:CCH). For further information, visit the Company's web site at www.nuinsco.ca.

MondayNov 03, 2008 4:30 am

Ausam Energy Corporation (TSX: AZE CN)

Ausam Energy Corporation (TSX: AZE CN) is focused on oil & natural gas development and exploration in the Gulf Coast of the United States. The company currently has two producing wells in Texas and Louisiana. Ausam Energy’s 19 prospects and leads located onshore in the Gulf Coast region of the United States encompass more than 90,000 gross acres (50,000 net acres) and diversifies the company’s portfolio in areas of known commercial petroleum production with established infrastructure and gas markets. For further information, visit the Company's web site at www.ausamenergy.com.

MondayNov 03, 2008 4:29 am

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST)

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST) is focused on developing, manufacturing, and commercializing medical products designed to fight infection and inflammation based on the company’s patented atomically disordered nanocrystalline silver technology. NUCRYST has found success developing and manufacturing Acticoat™ dressings with SILCRYST™ nanocrystals for Smith & Nephew plc. These products are currently in use by hospitals, clinics, burn centers, doctor’s offices, home healthcare agencies and nursing homes around the globe. For further information, visit the Company's web site at www.nucryst.com.

MondayNov 03, 2008 4:29 am

ATS Medical, Inc. (NASDAQ: ATSI)

ATS Medical, Inc. (NASDAQ: ATSI) is focused on providing novel products and services designed specifically for cardiac surgery. Over 160,000 ATS Open Pivot(R) Heart Valves have been implanted in patients around the globe. ATS’ 3f(R) brand includes multiple tissue heart valve product offerings at varying steps from market introductions and clinical trials to development projects that utilize less invasive valve replacement technology. For further information, visit the Company's web site at www.atsmedical.com.

MondayNov 03, 2008 4:29 am

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is focused on the development of specialty therapeutics for gastrointestinal and endocrine disorders. Currently, the company is progressing two late-stage programs: GATTEX™ (teduglutide), which is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection), which is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. For further information, visit the Company's web site at www.npsp.com.

MondayNov 03, 2008 4:28 am

Novelos Therapeutics, Inc. (OTC BB: NVLT)

Novelos Therapeutics, Inc. (OTC BB: NVLT), a biopharmaceutical company, has its focus on commercializing oxidized glutathione-based compounds for the treatment of Cancer and Hepatitis. The company’s lead compound in Phase 3 development for lung cancer under a Special Protocol Assessment (SPA) and Fast Track, NOV-002, acts together with chemotherapy as a chemoprotectant and chemopotentiator by regulating redox-sensitive cell signaling pathways. For further information, visit the Company's web site at www.novelos.com.

MondayNov 03, 2008 4:28 am

AtriCure, Inc. (NASDAQ: ATRC)

AtriCure, Inc. (NASDAQ: ATRC), a medical device company, is focused on leading the development, manufacturing and selling of novel cardiac surgical ablation systems intended to create precise lesions, or scars, in cardiac tissue. The FDA has approved the AtriCure Isolator® system, including its Isolator SynergyTM ablation clamps, and AtriCure’s multifunctional pen and CoolrailTM linear ablation device, for the destruction of heart tissue during surgical procedures. For further information, visit the Company's web site at www.atricure.com.

MondayNov 03, 2008 4:28 am

Novavax, Inc. (NASDAQ: NVAX)

Novavax, Inc. (NASDAQ: NVAX), a clinical stage biotechnology company, is focused on creating innovative vaccines that target a wide array of infectious diseases using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP based, potent, recombinant vaccines by leveraging new and efficient manufacturing approaches. Novavax’s long-term goal is to be able to deliver a customized vaccine in the midst of an epidemic. For further information, visit the Company's web site at www.novavax.com.

MondayNov 03, 2008 4:28 am

ArQule, Inc. (NASDAQ: ARQL)

ArQule, Inc. (NASDAQ: ARQL), a biotechnology company, is committed to researching and developing next-generation, small-molecule cancer therapeutics. The company’s lead product, ARQ 197, is currently in clinical-stage development. ArQule’s discovery efforts are focused on identifying novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate), an energy source for cells. For further information, visit the Company's web site at www.arqule.com.

MondayNov 03, 2008 4:27 am

NovaDel Pharma, Inc. (AMEX: NVD)

NovaDel Pharma, Inc. (AMEX: NVD), a specialty pharmaceutical company, is focused on developing oral spray formulations of a wide array of marketed therapeutics. NovaMist™, the Company's proprietary technology, allows drugs to be rapidly delivered directly into the bloodstream, which results in faster onset of action and may provide patient benefits in compliance, convenience and safety. Currently, NovaDel's most advanced candidates are designed to treat angina, insomnia, and nausea. For further information, visit the Company's web site at www.novadel.com.

Site Search

Company Search

Month: November 2008

Nuinsco Resources Limited (TSX: NWI CN)

Ausam Energy Corporation (TSX: AZE CN)

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST)

ATS Medical, Inc. (NASDAQ: ATSI)

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)

Novelos Therapeutics, Inc. (OTC BB: NVLT)

AtriCure, Inc. (NASDAQ: ATRC)

Novavax, Inc. (NASDAQ: NVAX)

ArQule, Inc. (NASDAQ: ARQL)

NovaDel Pharma, Inc. (AMEX: NVD)

Market Basics

Newsletter Publishers

Public Companies